Skip to main content
Maricer Escalon, MD, Oncology, Miami, FL, University of North Carolina Hospitals

MaricerPEscalonMD

Oncology Miami, FL

Breast Cancer, Hematologic Oncology

Associate Vice President at Lilly

Dr. Escalon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Escalon's full profile

Already have an account?

Education & Training

  • Imperial College
    Imperial CollegeExecutive MBA, 2014
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2002 - 2005
  • University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual Science
    University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual ScienceMSc, Clinical Research, emphasis on Immunology, 2005
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2002
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 1999
  • Florida State University
    Florida State UniversityBS, Biochemistry, 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2001 - 2026
  • AZ State Medical License
    AZ State Medical License 2019 - 2025
  • NC State Medical License
    NC State Medical License 2018 - 2022
  • TX State Medical License
    TX State Medical License 2002 - 2005

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Fellow of the Year Award MD Anderson
  • Young Investigator Award American Society of Clinical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose Protection
    Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose ProtectionApril 29th, 2021

Hospital Affiliations